JERSEY CITY, N.J., April 10, 2018 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovativeanti-infective therapies for difficult-to-treat and often life-threatening infections, today announced three poster presentations at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April
Title: In Vitro Activity of SCY-078, a Novel IV/Oral Glucan Synthase Inhibitor, against Aspergillus spp., Alone or in Combination with other Antifungal TherapiesPresenter: Mahmoud Ghannoum PhDDate and Time: Saturday, April 21, from 15:30-16:30 CETPoster Presentation #: PO164Session: Aspergillus in the laboratory
Title: Activity of SCY-078 and comparators against a collection of Aspergillus spp. including cryptic species and Cyp51A mutantsPresenter: Ana Alastruey-Izquierdo PhDDate and Time: Saturday, April 21, from 15:30-16:30 CETPoster Presentation #: PO165Session: Aspergillus in the laboratory
Title: SCY-078 Demonstrates Antifungal Activity Against Pneumocystis in a Prophylactic Murine Model of Pneumocystis PneumoniaPresenter: Stephen Barat PhDDate and Time: Sunday, April 22, from 13:30-14:30 CETPoster Presentation #: P1226Session: Update on Pneumocystis
The ECCMID 2018 posters will be available on the SCYNEXIS website following the event.
About SCYNEXISSCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. The SCYNEXIS team has extensive experience in the life sciences industry, discovering and developing more than 30 innovative medicines over a broad range of therapeutic areas. The Company's lead product candidate, SCY-078, is a novel IV/oral antifungal agent in Phase 2 clinical and preclinical development for the treatment of several serious and life-threatening invasive fungal infections caused by Candida and Aspergillus species. For more information, visit www.scynexis.com.
Investor RelationsSusan KimArgot PartnersTel: email@example.com
Media RelationsGeorge E. MacDougallMacDougall Biomedical CommunicationsTel: firstname.lastname@example.org
View original content:http://www.prnewswire.com/news-releases/scynexis-to-present-scy-078-data-at-the-28th-european-congress-of-clinical-microbiology-and-infectious-disease-eccmid-300625304.html
SOURCE SCYNEXIS, Inc.
Subscribe to our Free Newsletters!